Clinical trial · no report yet · Phase 1/Phase 2
MELT-MM
Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
- NCT06645678 ↗
- Recruiting
- YOUNGIL KOH
- 8 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 4 | |
| X threads | 3 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- Phase I/II Study of Mezigdomide and Elranatamab for Relapsed/Refractory Multiple Myeloma Patients
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Relapsed Refractory Multiple Myeloma (RRMM)
- Interventions
- Elranatamab; Mezigdomide; Dexamethasone
- Arms
- Treatment arm · Experimental
- Enrollment
- 75 (estimated)
- Primary outcomes
- Overall response rate (ORR)
- Sponsor
- YOUNGIL KOH
- Start
- Nov 26, 2024
- Primary completion
- Oct 1, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06645678 · updated Dec 3, 2025